生产企业：Samchundang Pharm
SCD-411 (SCD411) is Samchundang Pharm's biosimilar of Eylea (aflibercept 2 mg), an ophthalmic medicine used for age-related macular degeneration. Phase III clinical trials began in August 2020, aiming at US and Japanese approval. In December 2025, the FDA accepted the proposed aflibercept biosimilar aBLA submitted with partner Fresenius Kabi. After earlier settlements in the US and Canada, Samchundang Pharm reached a global settlement with Regeneron Pharmaceuticals and Bayer in August 2026, dismissing pending patent litigation in Europe, Japan, and South Korea and clearing the path for commercialization.
SCD-411 (SCD411) is Samchundang Pharm's biosimilar of Eylea (aflibercept 2 mg), an ophthalmic medicine used for age-related macular degeneration. Phase III clinical trials began in August 2020, aiming at US and Japanese approval. In December 2025, the FDA accepted the proposed aflibercept biosimilar aBLA submitted with partner Fresenius Kabi. After earlier settlements in the US and Canada, Samchundang Pharm reached a global settlement with Regeneron Pharmaceuticals and Bayer in August 2026, dismissing pending patent litigation in Europe, Japan, and South Korea and clearing the path for commercialization.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
